A phase III trial comparing dovitinib with sorafenib in patients with advanced RCC who had progressed on previous VEGF-targeted therapies and mTOR therapies failed to show a survival benefit of dovitinib [204]. The gene discussed is VEGFA; the disease is renal cell carcinoma.